The
slide to be stained for progesterone receptor
(PR) comprised:
1. Uterine cervix, 2. Ductal breast carcinoma, PR negative, 3.
Ductal breast carcinoma, PR 40-60 % positive, 4. Ductal breast
carcinoma, PR 80–100 % positive. (The block was identical to the
block used in B2 2006).
The positivity of the 3 ductal breast carcinomas was verified in 4
reference IHC laboratories.
All tissues were fixed in 10% neutral buffered formalin.
Criteria for assessing a PR staining as optimal included:
- A strong and distinct nuclear staining of
the columnar epithelial cells, the basal squamous epithelial cells
and the stromal cells in the uterine cervix.
- A moderate to strong and distinct nuclear
staining of the ductal breast carcinomas no. 3 and 4 in accordance
with the PR status.
- No nuclear staining of the PR negative
ductal breast carcinoma no. 2 – only epithelial cells in remnants
of normal glands should show a positive reaction.
95 laboratories submitted stains. At the
assessment 54 achieved optimal marks (57 %), 22 good (23 %), 4
borderline (4 %) and 15 poor marks (16 %).
The following Abs were used:
mAb clone PgR 636 (Dako, n=41)
mAb clone 16 (Novocastra, n=13; Monosan n=1)
mAb clone 1A6 (Novocastra, n=4; Ventana n=1)
mAb clone PgR 1294 (Dako, n=2)
mAb clone PR 88 (BioGenex, n=1)
mAb clone PR-1 (Klinipath, n=1)
mAb clone hPRa 2 + hPRa 3 (NeoMarkers, n=1)
rmAb clone 1E2 (Ventana, n=23)
rmAb clone SP2 (NeoMarkers, n=6; Diagnostic BioSystems, n=1)
Optimal staining for PR in this assessment was obtained with
the mAb clone PgR 636 (24 out of 41), mAb clone 16 (6
out of 14), the rmAb clone 1E2 (17 out of 23) and the rmAb
clone SP2 (3 out of 7).
Using the mAb clone PgR 636 the protocols giving an optimal
result were all based on heat induced epitope retrieval (HIER) using
Tris-EDTA/EGTA pH 9 (18/29)*, Citrate pH 6 (2/6), Bond Epitope
Retrieval Solution 2 (Bond, Vision Biosystems) (2/2), EDTA/EGTA pH8
(1/1) or EnVision™ FLEX, High pH (Dako) (1/1) as HIER buffer. The
mAb was typically diluted in the range of 1:50 – 1:1.000 depending on
the total sensitivity of the protocol employed. Using these protocol
settings 32 out of 37 (86 %) laboratories produced a sufficient
staining marked as optimal.
* (number of optimal results/number of
laboratories using this buffer)
Using the mAb clone 16 the protocols giving an optimal result
were all based on HIER using
Tris-EDTA/EGTA pH 9 (4/6)*, Bond Epitope Retrieval Solution 2 (Bond,
Vision Biosystems) (1/1), 1mM EDTA pH 9 (1/1) as HIER buffer. The
mAb was typically diluted in the range of 1:100 – 1:500 depending on
the total sensitivity of the protocol employed. Using these protocol
settings 6 out of 8 (75 %) laboratories produced a sufficient
staining (optimal or good).
* (number of optimal results/number of
laboratories using this buffer)
Using the rmAb clone 1E2 the protocols giving an optimal
result were all based on HIER using Cell Conditioning 1 (BenchMark,
Ventana) (14/19)*, EDTA/EGTA pH8 (2/3) or Cell Conditioning 2 (BenchMark,
Ventana) (1/1) as HIER buffer. The rmAb was used as a Ready-To-Use
antibody. Using these protocol settings 22 out of 23 (96 %)
laboratories produced a sufficient staining (optimal or good).
* (number of optimal results/number of
laboratories using this buffer)
Using the rmAb clone SP2 the protocols giving an optimal
result were all based on HIER using Cell Conditioning 1 (BenchMark,
Ventana) (1/3)*, Tris-EDTA/EGTA pH 9 (1/2) or Target Retrieval
Solution pH 6,1 (TRS, Dako) (1/1) as HIER buffer. The rmAb was
typically diluted in the range of 1:100 – 1:350 depending on the
total sensitivity of the protocol employed. Using these protocol
settings 4 out of 6 (75 %) laboratories produced a sufficient
staining (optimal or good).
* (number of optimal results/number of
laboratories using this buffer)
The most frequent causes of insufficient
staining were:
- Too low concentration of the primary antibody
- Less successful primary antibody
- Insufficient epitope retrieval – too short efficient HIER time
In this assessment (and in concordance with the observation in the
previous PR assessment, run B2, 2006) almost all laboratories were
able to demonstrate PR in the ductal breast carcinoma no. 4 with
80-100 % positivity and a strong staining intensity, whereas the
prevalent feature of the insufficient staining was a too weak or
entirely false negative staining of the ductal breast carcinoma no.
3 with 40-60 % positivity and a moderate staining intensity.
A too weak or false negative staining was seen in 89 % of the
insufficient results (17 out of 19), while in 11 % (2 out of 19) a
too strong staining and false positive PR staining reaction was
seen.
This was the third NordiQC assessment of PR. The
proportion of sufficient results has increased relatively constant
through the individual assessments – from 68% in run 10 2004, to 74%
in run B2 2006
to 80% in the present run. Multiple
factors contribute to the improvement, but especially the focus on
the choice of antibody and appropriate control as
normal cervix uteri for PR seem to be the central parameters for an
optimal demonstration of PR.
The rmAb clone 1E2 and the
mAb clone PGR 636 seem to be the most robust clones for the PR
demonstration, as respectively 93% and 80% of all submitted stains based on these clones were assessed as sufficient in run
B2 and B4.
| |
Run B2 2006 |
Run B4 2007 |
Total |
| |
Protocols |
Sufficient |
Protocols |
Sufficient |
Protocols
analyzed |
Sufficient |
| MAb clone 1A6 |
6 |
4 |
5 |
3 |
11 |
7 (64%) |
| MAb clone 16 |
21 |
17 |
14 |
8 |
35 |
25 (71%) |
| MAb clone PGR 636
|
39 |
31 |
41 |
33 |
80 |
64 (80%)
|
| RmAb 1E2 |
5 |
4 |
23 |
22 |
28 |
26 (93%) |
| RmAb SP2 |
4 |
2 |
7 |
4 |
11 |
6 (55%) |
Table 1. Number
of protocols submitted in the last two PR assessments, the number of
sufficient results and Abs used.
Also the specific tailored recommendations to the laboratories in
run 10 and B2 achieving an insufficient staining seem to contribute
to the improvement of the pass rate. The three main recommendations
given were following:
1) Consider change of primary antibody
2) Increase the primary Ab concentration
3) Optimize HIER, i.e., prolong heating time and/or substitute
Citrate pH 6 with an alkaline buffer (Tris/EDTA pH 9 or equivalent).
Among laboratories participating in all three runs, 37
recommendations have been given. The results are indicated in Table
2.
| |
Followed recommendations* |
| |
Yes |
No |
| Number of laboratories
advised |
30 |
7 |
| Number of laboratories
improved |
25 (83%) |
0 (0%) |
* 9 laboratories
changed their entire system – all 9 improved their mark from
insufficient.
Table 2. Improvement of results from insufficient to sufficient as
consequence of recommendations given to 37 laboratories
participating in all three PR assessments.
As described previously the uterine cervix
seems to be an appropriate control for the evaluation of the
sensitivity of the PR staining. In an optimal protocol almost all
the columnar epithelial cells, the basal squamous epithelial cells
and the stromal cells shall show a strong and distinct nuclear
staining with only a minimal cytoplasmic reaction.
Conclusion
In particular the mAb clones PGR 636 and 16 and the rmAb clone 1E3
are all well performing and robust Abs for PR. HIER is mandatory.
For optimal demonstration an alkaline buffer is preferable. The
concentration of the Ab must be carefully calibrated on an
appropriate control such as the uterine cervix. |